Articles By Jiha Lee, MD
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex
ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania.
Read Article
Falls Hide in Plain Sight in Rheumatic Disease
Katherine Wysham, MD, in the session “Rheumatology for Every Age” at ACR 2026 noted that falls are common in people with arthritis and underreported. A fall tends to start a cycle: lost confidence, less going out, reduced social participation, deconditioning, and then more falls and fractures. As patients age, rheumatologists will see this cycle more often, and about 25% of hip fracture patients die within a year.
Read Article
Biologic Dosing and Obesity
A 46-year-old with psoriatic arthritis and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Switch class, optimize methotrexate, or ask whether the dose itself is too low?
Read Article
Is Obesity Inflating Your Disease Activity Scores?
Obesity is common in inflammatory arthritis, with an estimated 60-70% of people with rheumatoid arthritis and 70-80% of people with psoriatic arthritis also living with overweight or obesity. But does obesity affect disease activity and outcomes in inflammatory arthritis?
Read Article
Three Tips to Stay on Muscarinic Agonists in Sjögren's Disease
Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. A rheumatology talk in the session noted that recent phase III trials of ianalumab, dazodalibep and telitacicept improved ESSDAI scores, with only some evidence of benefit for dryness itself. Symptomatic care therefore still carries the load. Masafumi Moriyama, DDS, PhD, offered practical insight from the oral health side.
Read Article
Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner
At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.
Read Article
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
At EULAR 2026, speakers of the session “Catching Your Breath: Unravelling RA Associated Interstitial Lung Disease (ILD)” noted RA-ILD is one of the few outcomes not improving in the biologic era. Three abstracts reinforce that message and make the case for a practical, low-cost screening tool that is already in most rheumatologists’ hands.
Read Article
What’s New in Psoriatic Arthritis: A Whirlwind Tour
At the "What Is New in Psoriatic Arthritis" session at EULAR 2026, Professor Dennis McGonagle (Leeds, UK) took the audience on a whirlwind yet compact tour of the field, touching on three themes: the pathophysiology of PsA, individualization of clinical management, and emerging research and future directions.
Read Article
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology
A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.
Read Article
Ianalumab Shows Phase 3 Success in Sjögren’s: Is It Clinically Meaningful?
On the final day of ACR25, late-breaking abstract #24 drew particular attention, presenting results from the first positive Phase 3 trials of a potential systemic treatment for a disease that has long lacked one.
Read Article
